Novo Nordisk, Omega Therapeutics, and Cellarity have announced that Novo Nordisk has entered into separate research collaborations with each company. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity’s platform to develop a small molecule therapy against this disease.
These are the first two programmes signed under the framework collaboration between Flagship Pioneering and Novo Nordisk to leverage Flagship’s bioplatform companies to develop novel treatment approaches for cardiometabolic diseases.
First two programmes under Flagship framework collaboration
The previously announced partnership brings together Novo Nordisk’s Bio Innovation Hub, an R&D unit designed to accelerate the development of therapeutics via co-creative partnerships with academia, biotechs, and venture capital groups, and Pioneering Medicines, Flagship’s drug development initiative leveraging Flagship Pioneering’s unique ecosystem of bioplatform capabilities.
Each company, Novo Nordisk and Pioneering Medicines will jointly advance these respective programmes through preclinical development and conduct foundational activities, after which point Novo Nordisk could advance the programmes into clinical studies. Under the terms of the respective agreements, Novo Nordisk will reimburse R&D costs. Additionally, each agreement may pay up to 532 million dollars in upfront, development and commercial milestone payments, as well as tiered royalties on annual net sales of a licensed product, to be shared between the respective companies and Flagship’s Pioneering Medicines.
Paul Biondi, president, Pioneering Medicines, and executive partner, Flagship Pioneering said: “These collaboration agreements with Omega and Cellarity are an exciting demonstration of how our partnership with Novo Nordisk is leveraging the unique bioplatform technologies within the Flagship ecosystem to develop potentially transformational medicines. Bringing these innovative platforms together with Novo Nordisk’s deep expertise in cardiometabolic disease we have incredible potential to make a bigger leap forward for patients.
Marcus Schindler, executive vice president and chief scientific officer at Novo Nordisk said: “This is an important moment in our partnership with Flagship Pioneering. We look forward to advancing these research programmes with Omega and Cellarity in the coming years as we explore bold new treatment strategies with the potential to make a significant impact for people living with obesity or MASH. Novo Nordisk is committed to advancing new treatment options for people living with cardiometabolic diseases. To that end, it is essential that we complement our internal research with external innovation and work with partners who are bringing forward cutting-edge technology. Both companies offer differentiated and novel approaches, including Omega’s expertise in controlled epigenomic modulation and Cellarity’s deep insights into applying human data and artificial intelligence to the development of new medicines.”